OsStic
Pre-clinical- Indications
- Bone fractures, Periarticular fractures, Bone void filling
Company intelligence / Profile preview
OsStic®, the company’s lead product, is a synthetic injectable bone void filler and bioadhesive designed for trauma, spinal, and dental applications. It has received FDA Breakthrough Device Designation in 2023 for its ability to provide structural stability in peri-articular fractures where standard fixation is insufficient. Extensive in-vivo studies have demonstrated its safety and efficacy as a mechanically enhanced adhesive for bone repair.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biomimetic Innovations.